Overview

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in th

Status:
Active, not recruiting

Trial end date:
2020-05-01

Target enrollment:

Participant gender:

Summary

A multicenter, open label cohort Phase 1 dose finding study to evaluate tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 for oral administration in adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), which is resistant to the 2-nd generation Bcr-Abl inhibitors or has T315I mutation in the BCR-ABL gene.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fusion Pharma LLC

Collaborators:

Data Matrix Solutions
Data Matrix, LTD
OCT Rus, LLC
Skolkovo Innovation Center